Lexeo Therapeutics (LXEO) Cash from Financing Activities (2022 - 2026)

Lexeo Therapeutics has reported Cash from Financing Activities for 5 years, with the latest figure at $2.5 million in Q1 2026.

• Quarterly Cash from Financing Activities rose 22190.91% year-over-year to $2.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $219.2 million (up 164739.1% YoY) and the FY2025 annual result came in at $216.8 million, up 144.2% from the prior year.
• Cash from Financing Activities fell to $2.5 million in Q1 2026 per LXEO's latest filing, from $143.8 million in the prior quarter.
• Over five years, Cash from Financing Activities peaked at $143.8 million in Q4 2025 and troughed at -$98000.0 in Q1 2023.
• A 5-year average of $29.4 million and a median of $171500.0 in 2024 frame the typical range for Cash from Financing Activities.
• The sharpest annual moves came in 2024 and 2025: Cash from Financing Activities tumbled 101.84% in 2024, then jumped 148318.56% in 2025.
• Over 5 years, Cash from Financing Activities stood at -$81000.0 in 2022, then jumped by 123644.44% to $100.1 million in 2023, then tumbled by 100.1% to -$97000.0 in 2024, then surged by 148318.56% to $143.8 million in 2025, then sank by 98.29% to $2.5 million in 2026.
• According to Business Quant data, Cash from Financing Activities over the past three periods registered $2.5 million, $143.8 million, and $52000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.